Detalhe da pesquisa
1.
Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.
Proc Natl Acad Sci U S A
; 119(38): e2202727119, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099300
2.
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 24(2): 162-174, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36623515
3.
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Gynecol Oncol
; 160(3): 786-792, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33375991
4.
Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Gynecol Oncol
; 156(2): 407-414, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31839337
5.
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Nat Commun
; 15(1): 2805, 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555285
6.
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCA-mutant ovarian cancer.
Sci Transl Med
; 15(701): eadd7872, 2023 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37343085
7.
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
J Clin Oncol
; 41(4): 871-880, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36256912
8.
Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
Sci Transl Med
; 14(652): eabn1926, 2022 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35857626
9.
Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer.
Cancer Res Commun
; 2(10): 1282-1292, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36311816
10.
Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
Cold Spring Harb Mol Case Stud
; 7(2)2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33832919
11.
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.
Clin Cancer Res
; 27(23): 6314-6322, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34580114
12.
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
NAR Cancer
; 3(3): zcab028, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34316715
13.
Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer.
Cancer Res
; 80(4): 857-867, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31822495
14.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Clin Cancer Res
; 26(16): 4268-4279, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32398324
15.
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
Nat Commun
; 10(1): 5661, 2019 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31827092
16.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer Discov
; 9(2): 210-219, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425037
17.
Molecular phylogenetics and species-level systematics of Baylisascaris.
Int J Parasitol Parasites Wildl
; 7(3): 450-462, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568876
18.
DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma.
Pancreas
; 50(5): e50-e52, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34106577